Israel - hebreiska - Ministry of Health

takeda israel ltd - lanthanum as carbonate hydrate - אבקה - lanthanum as carbonate hydrate 750 mg - lanthanum carbonate

Israel - hebreiska - Ministry of Health

abic ltd. - propranolol hydrochloride - טבליה - propranolol hydrochloride 10 mg - propranolol - propranolol - 1. management of angina pectoris. 2. control of essential and renal hypertension essential tremor most forms of cardiac dysrhythmias. 3. as an adjunct in the management of tachycardias and arrhythmias due to thyrotoxicosis and thyrotoxic crises hypertrophic obstructive cardiomyopathy pheochromocytoma (with an alpha-blocker). 4. deralin tablets are also indicated for long-term prophylaxis following recovery from acute myocardial infarction (treatment to be initiated by a hospital physician). 5. migraine prophylaxis.

Israel - hebreiska - Ministry of Health

abic ltd. - propranolol hydrochloride - טבליה - propranolol hydrochloride 40 mg - propranolol - propranolol - 1. management of angina pectoris. 2. control of essential and renal hypertension essential tremor most forms of cardiac dysrhythmias. 3. as and adjunct in the management of tachycardias and arrhythmias due to thyrotoxicosis and thyrotoxic crises hypertrophic obstructive cardiomyopathy pheochromocytoma (with an alpha blocker). 4. deralin is also indicated for long term prophylaxis following recovery from acute myocardial infarction (treatment to be initiated by a hospital physician) . 5. migraine prophylaxis.

Israel - hebreiska - Ministry of Health

pfizer pharmaceuticals israel ltd - sirolimus - תמיסה (פומי) - sirolimus 1 mg/ml - sirolimus - sirolimus - rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. it is recommended that rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.

Israel - hebreiska - Ministry of Health

bayer israel ltd - recombinant human coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - recombinant human coagulation factor viii 1000 iu - coagulation factor viii

Israel - hebreiska - Ministry of Health

bayer israel ltd - recombinant human coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - recombinant human coagulation factor viii 2000 iu - coagulation factor viii

Israel - hebreiska - Ministry of Health

bayer israel ltd - recombinant human coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - recombinant human coagulation factor viii 250 iu - coagulation factor viii

Israel - hebreiska - Ministry of Health

bayer israel ltd - recombinant human coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - recombinant human coagulation factor viii 500 iu - coagulation factor viii

Israel - hebreiska - Ministry of Health

cts chemical industries ltd, israel - ferrous as iron iii hydroxide polymaltose compl.; folic acid - טבליה - folic acid 0.4 mg; ferrous as iron iii hydroxide polymaltose compl. 100 mg - ferrous amino acid complex - ferrous amino acid complex - prevention and treatment of anemia caused by iron and folic acid deficiency including anemia of pregnancy and lactation.

Israel - hebreiska - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 1000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob